ARIUS Research Inc. http://www.alacrastore.com/company-snapshot/ARIUS_Research_Inc-2517863 Saturday, September 06, 2008 7:41:01 PM 2517863 ARIUS Research Inc. en AlacraStore RSS Builder 1.0 30 CANADA - Roche Holding AG definitively agreed to acquire all the outstanding common stock of Arius Research Inc, a biotechnology company, for #.## Canadian dollars ($#.### US) in cash per share, or a total value of C$###.### mil ($###.### mil). The transaction was subject to customary closing conditions and regulatory approvals.7/24/2008 2:29:22 PM77119M04045477119M040454Roche Holding AGArius Research IncRoche Holding AGArius Research Inchttp://www.alacrastore.com/storecontent/Thomson_M%26A/Roche_Holding_AG_acquires_Arius_Research_Inc-1998030040sdc/19980300401998030040Copyright © 2008, Thomson Financial, All Rights ReservedZurichDrugsSwitzerlandPharmaceutical preparations2834FFForeignPublicROG2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2869:Industrial organic chemicals, nec2899:Chemicals and chemical preparations, nec3841:Surgical and medical instruments and apparatus6719:Offices of holding companies, nec8731:Commercial physical and biological research2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2869:Industrial organic chemicals, nec2899:Chemicals and chemical preparations, nec3841:Surgical and medical instruments and apparatus6719:Offices of holding companies, nec8731:Commercial physical and biological researchTorontoDrugsCanadaBiological products, except diagnostic substances2836FFForeignPublicARI121305001Mnfr pharm,med instrBiotech coCashCash OnlyCommon StockOption633101003Jul 24 20080.000008.60100-11.21500-10.19900-5.40100-3.04000-3.39900-3.059005.643000.515000.00300-11.62900-0.27200-12.19800-11.721002.503000.0150011.64500SFR31 Dec 070.000008622.789000.0000040753.5230067902.80900Swiss Franc31 May 0830 Nov 0730 Nov 0630 Nov 0530 Nov 0430 Nov 031.007001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.0000026.0000027.0000028.0000029.0000030.0000031.0000032.0000033.0000034.0000035.0000036.0000037.0000038.0000039.0000040.0000041.0000042.0000043.0000044.0000045.00000Roche Holding AG,headquartered in Basel,Switzerland, manufacturespharmaceuticals, medicines,diagnostics, chemicals,diagnostic kits, and medicalinstruments. The Group'sprincipal activities are todiscover, develop, manufactureand market novel health caresolutions. The Group operatesthrough two segments namelyPharmaceuticals andDiagnostics. ThePharmaceuticals divisionincludes prescription andmanufacturing ofpharmaceutical products. ThePharmaceutical segment hasthree sub-divisions namelyRoche Prescription, GenentechPrescription and ChugaiPrescription. Diagnosticsegment provides products andservices in all fields ofmedical testing. It alsoprovides reagents and testkits for molecular and cellbiology, analytical systemsand reagents for clinicalchemistry, immunochemistry,hematology and coagulation.Diagnostics division consistsof five business areas:Diabetes Care, Near PatientTesting, CentralizedDiagnostics, MolecularDiagnostics and AppliedScience. It operates inSwitzerland, European Union,United States, North America,Latin America, Japan, Asia,Africa, Australia and Oceania.The company was founded in1896.Roche Holding AG, headquartered in Basel, Switzerland,manufactures pharmaceuticals, medicines, diagnostics,chemicals, diagnostic kits, and medical instruments. TheGroup's principal activities are to discover, develop,manufacture and market novel health care solutions. TheGroup operates through two segments namely Pharmaceuticalsand Diagnostics. The Pharmaceuticals division includesprescription and manufacturing of pharmaceutical products.The Pharmaceutical segment has three sub-divisions namelyRoche Prescription, Genentech Prescription and ChugaiPrescription. Diagnostic segment provides products andservices in all fields of medical testing. It also providesreagents and test kits for molecular and cell biology,analytical systems and reagents for clinical chemistry,immunochemistry, hematology and coagulation. Diagnosticsdivision consists of five business areas: Diabetes Care,Near Patient Testing, Centralized Diagnostics, MolecularDiagnostics and Applied Science. It operates in Switzerland,European Union, United States, North America, Latin America,Japan, Asia, Africa, Australia and Oceania. The company wasfounded in 1896.Roche Holding AG, headquartered in Basel, Switzerland, manufactures pharmaceuticals, medicines, diagnostics, chemicals, diagnostic kits, and medical instruments. The Group's principal activities are to discover, develop, manufacture and market novel health care solutions. The Group operates through two segments namely Pharmaceuticals and Diagnostics. The Pharmaceuticals division includes prescription and manufacturing of pharmaceutical products. The Pharmaceutical segment has three sub-divisions namely Roche Prescription, Genentech Prescription and Chugai Prescription. Diagnostic segment provides products and services in all fields of medical testing. It also provides reagents and test kits for molecular and cell biology, analytical systems and reagents for clinical chemistry, immunochemistry, hematology and coagulation. Diagnostics division consists of five business areas: Diabetes Care, Near Patient Testing, Centralized Diagnostics, Molecular Diagnostics and Applied Science. It operates in Switzerland, European Union, United States, North America, Latin America, Japan, Asia, Africa, Australia and Oceania. The company was founded in 1896.1.000002.000003.000004.000005.000006.000007.000008.000009.00000Arius Research Inc is abiotechnology companyheadquartered in Toronto,Ontario. The company focuseson discovering and developingthe next wave of antibodytherapeutics to treat cancerand other diseases. Thecompany was founded in 1999.Arius Research Inc is a biotechnology company headquarteredin Toronto, Ontario. The company focuses on discovering anddeveloping the next wave of antibody therapeutics to treatcancer and other diseases. The company was founded in 1999.Arius Research Inc is a biotechnology company headquartered in Toronto, Ontario. The company focuses on discovering and developing the next wave of antibody therapeutics to treat cancer and other diseases. The company was founded in 1999.0.000000.000000.0000051.39000YCanadian Dollar23 Jul 08Wed, 23 Jul 2008 00:00:00 ESTDate Announced: 07/23/2008Date Effective:MergerFriendly0.000000.000000.00000-2.165000.000002.44000Price/Share0.00000122.185 Canadian Dollar122.18500122.18500113.657 Canadian Dollar113.657000.000000.000002.422002.42200113.65700113.657 Canadian Dollar0.99300N60.906000.000000.000000.000000.000000.00000121.28700121.28700-10.969000.194000.187000.17900-0.871000.000000.00000100.00000-10.20400-9.8400020.27800-9.3820045.71900-10.57900-10.0850049.149000.000000.000000.000000.000000.000000.000000.000000.000000.000005.643000.0000033.134000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.00000CANADA - Roche Holding AGdefinitively agreed to acquireall the outstanding commonstock of Arius Research Inc, abiotechnology company, for2.44 Canadian dollars ($2.422US) in cash per share, or atotal value of C$122.185 mil($121.287 mil). Thetransaction was subject tocustomary closing conditionsand regulatory approvals.CANADA - Roche Holding AG definitively agreed to acquire all the outstanding common stock of Arius Research Inc, a biotechnology company, for 2.44 Canadian dollars ($2.422 US) in cash per share, or a total value of C$122.185 mil ($121.287 mil). The transaction was subject to customary closing conditions and regulatory approvals.CANADA - Roche Holding AG definitively agreed to acquire all the outstanding common stockof Arius Research Inc, a biotechnology company, for 2.44 Canadian dollars ($2.422 US) incash per share, or a total value of C$122.185 mil ($121.287 mil). The transaction wassubject to customary closing conditions and regulatory approvals.CANADA - Roche Holding AG definitively agreed to acquire all the outstanding common stock of Arius Research Inc, a biotechnology company, for 2.44 Canadian dollars ($2.422 US) in cash per share, or atotal value of C$122.185 mil ($121.287 mil). The transaction was subject to customary closing conditions and regulatory approvals.CANADA - Roche Holding AG definitively agreed to acquire all the outstanding common stock of Arius Research Inc, a biotechnology company,for 2.44 Canadian dollars ($2.422 US) in cash per share, or a total value of C$122.185 mil ($121.287 mil). The transaction was subject tocustomary closing conditions and regulatory approvals.$ 112.822 - Merrill Lynch - Adv0.00000Merrill Lynch & Co Inc1.00000Aquilo Partners IncReedland Capital PartnersDundee Securities Corporation1.000002.000003.00000$ 112.822 - Aquilo Partners Inc - Adv$ 112.822 - Reedland Capital Partners - Adv$ 112.822 - Dundee Securities Corporation - Adv0.000000.000000.00000Pending53307.000009761.0000046133.0000076866.000000.11800-11.13900-10.13000-5.36400-3.01900-3.37600-3.038005.60500-11.55000-0.25000-0.18000-0.28000-0.46000-0.37000-0.270005.605008.9820019.19500-0.970001.841002.85900-11.05700-6.44400-2.91400-3.43200-1.82600-12.11500-10.60800-6.44400-3.11400-3.43200-3.09400-11.641001.144002.848000.249000.177000.047002.4860011.5660015.3680023.210001.010003.854003.79000Status:PendingC-9.03700nm0.0000020.6640020.6640.000000.000000.00000114.34500122.117005.64300290.0750041.904000.00000-10.5790021.799002836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations121305001ZurichSwitzerland2834ForeignPublicROG2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations633101003TorontoCanada2836ForeignPublicARI121.28700113.65700112.8220056.65500Fasken Martineau DuMoulin LLPDeal InformationThomson Financial Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/newstex/PRN-0001-26877923newstex/PRN-0001-26877923xml TORONTO, Jul. ##, #### (Canada NewsWire Group delivered by Newstex) -- /CNW Telbec/ -- OrbiMed Advisors, LLC announced today the filing of the following press release and early warning report: "PRESS RELEASE AND EARLY WARNING REPORT...11000000110020000800000008003000080030020400000004016000040160050100000001005000010050027/23/2008 6:16:53 PM180000001801600018022000Canada NewsWire GroupPRN-0001-26877923ARIUS RESEARCH INCARINewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0001-26877925newstex/PRN-0001-26877925xml TORONTO, Jul. ##, #### (Canada NewsWire Group delivered by Newstex) -- /CNW Telbec/ -- Efficacy Capital, Ltd. announced today the filing of the following press release and early warning report: "PRESS RELEASE AND EARLY WARNING REPORT...11000000110020000800000008003000080030020100000001005000010050020400000004016000040160057/23/2008 6:16:53 PM180000001802200018016000Canada NewsWire GroupPRN-0001-26877925ARIUS RESEARCH INCARINewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0001-26853364newstex/PRN-0001-26853364xml BASEL, Switzerland and TORONTO, Jul. ##, #### (Canada NewsWire Group delivered by Newstex) -- /CNW/ -- Roche (SWX: ROG) and ARIUS Research Inc. (TSX:ARI) today announced that the two companies have signed a definitive agreement for...070000000700500007003000070030010701400007014008070140120700100007001004040000000401600004016005040020000400200604009000040090021300000013010000130100057/23/2008 2:16:49 AM1800000018016000180200001801000019000000190020001900200719002018Canada NewsWire GroupPRN-0001-26853364ARI NETWORK SERVICES INCARIUS RESEARCH INCGENENTECH INCARIARISDNANewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26853349newstex/PRN-0005-26853349xml Jul. ##, #### (PR Newswire delivered by Newstex) -- BASEL, Switzerland and TORONTO, July ## /PRNewswire-FirstCall/ - Roche (SWX: ROG) and ARIUS Research Inc. (TSX:ARI) today announced that the two companies have signed a definitive...0700000007005000070030000700300107014000070140080700100007001004040000000401600004016005040020000400200604009000040090021300000013010000130100057/23/2008 2:16:49 AM1800000018016000180200001801000019000000190020001900200719002018PR Newswire USPRN-0005-26853349ARI NETWORK SERVICES INCARIUS RESEARCH INCARIARISNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26591167newstex/PRN-0005-26591167xml Jul. ##, #### (PR Newswire delivered by Newstex) -- TORONTO, July ## /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced...0700000007005000040000000400200004002006040020010401600004016001040160180401604704016013070030000700300107001000070010040701400007014008070140040701401213000000130020001300200513010000130100057/11/2008 8:16:50 AM180000001801200018004000180150001900000019001000190010141900200019002012PR Newswire USPRN-0005-26591167ARI NETWORK SERVICES INCARIUS RESEARCH INCARIARISNewsNewstex